This TIP, Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction, provides consensus‐ and evidence‐based guidance on the use of buprenorphine, a new option for the treatment of opioid addiction. The goal of this TIP is to provide information that physicians can use to make practical and informed decisions about the use of buprenorphine to treat opioid addiction. The Guidelines address a number of topic areas related to this goal, including the physiology and pharmacology of opioids, opioid addiction, and treatment with buprenorphine; the screening and assessment of opioid addiction problems; detailed protocols for opioid addiction treatment with buprenorphine; management of special populations; and policies and procedures related to office‐based opioid addiction treatment under the paradigm established by the Drug Addiction Treatment Act of 2000. This TIP represents another step by CSAT toward its goal of bringing national leaders together to improve substance use disorder treatment in the United States.

Contents
• Foreword
• Executive Summary
• 1 Introduction
• 2 Pharmacology
• 3 Patient Assessment
• 4 Treatment Protocols
• 5 Special Populations
• 6 Policies and Procedures
• Appendix A. Bibliography
• Appendix B Assessment and Screening Instruments
• Appendix C DSM‐IV‐TR Material
• Appendix D Consent to Release of Information Under Title 42, Part 2, Code of Federal Regulations
• Appendix E Clinical Toolbox: Chapter 3 Supplemental Information
• Appendix F Federation of State Medical Boards—Model Policy Guidelines for Opioid Addiction Treatment in the Medical Office
• Appendix G Stages of Change
• Appendix H Sample Treatment Agreement/Contract
• Appendix I Glossary
• Appendix J Field Reviewers